Drugs / Culmerciclib
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07666555 | Jun 2026 → Jun 2028 expected | breast cancer | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT07616453 | May 2026 → May 2028 expected | hormone receptor-positive breast cancer | Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Culmerciclib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07616453 ↗ |
| Action | Inhibit | “CDK2/4/6 inhibitor” NCT07616453 ↗ |
| Target | CDK2 | “CDK2/4/6 inhibitor” NCT07616453 ↗ |